Pd Rx Pharmaceutical Stock Performance
| PDRX Stock | USD 3.33 0.00 0.00% |
On a scale of 0 to 100, Pd-Rx Pharmaceutical holds a performance score of 12. The company owns a Beta (Systematic Risk) of 0.0264, which implies not very significant fluctuations relative to the market. As returns on the market increase, Pd-Rx Pharmaceutical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Pd-Rx Pharmaceutical is expected to be smaller as well. Please check Pd-Rx Pharmaceutical's risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and day median price , to make a quick decision on whether Pd-Rx Pharmaceutical's current price history will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Pd Rx Pharmaceutical are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile basic indicators, Pd-Rx Pharmaceutical showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Pd-Rx |
Pd-Rx Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 280.00 in Pd Rx Pharmaceutical on November 16, 2025 and sell it today you would earn a total of 53.00 from holding Pd Rx Pharmaceutical or generate 18.93% return on investment over 90 days. Pd Rx Pharmaceutical is currently generating 0.287% in daily expected returns and assumes 1.8723% risk (volatility on return distribution) over the 90 days horizon. In different words, 16% of pink sheets are less volatile than Pd-Rx, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pd-Rx Pharmaceutical Target Price Odds to finish over Current Price
The tendency of Pd-Rx Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 3.33 | 90 days | 3.33 | about 9.82 |
Based on a normal probability distribution, the odds of Pd-Rx Pharmaceutical to move above the current price in 90 days from now is about 9.82 (This Pd Rx Pharmaceutical probability density function shows the probability of Pd-Rx Pink Sheet to fall within a particular range of prices over 90 days) .
Pd-Rx Pharmaceutical Price Density |
| Price |
Predictive Modules for Pd-Rx Pharmaceutical
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Pd Rx Pharmaceutical. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Pd-Rx Pharmaceutical Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Pd-Rx Pharmaceutical is not an exception. The market had few large corrections towards the Pd-Rx Pharmaceutical's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Pd Rx Pharmaceutical, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Pd-Rx Pharmaceutical within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.27 | |
β | Beta against Dow Jones | 0.03 | |
σ | Overall volatility | 0.24 | |
Ir | Information ratio | 0.11 |
Pd-Rx Pharmaceutical Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Pd-Rx Pharmaceutical for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Pd Rx Pharmaceutical can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Pd Rx Pharmaceutical currently holds about 104.55 K in cash with (465.77 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06. |
Pd-Rx Pharmaceutical Fundamentals Growth
Pd-Rx Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Pd-Rx Pharmaceutical, and Pd-Rx Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pd-Rx Pink Sheet performance.
| Return On Equity | 0.25 | |||
| Return On Asset | 0.0556 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 4.45 M | |||
| Shares Outstanding | 1.72 M | |||
| Price To Earning | 3.33 X | |||
| Price To Sales | 0.40 X | |||
| Revenue | 21.6 M | |||
| EBITDA | 991.1 K | |||
| Cash And Equivalents | 104.55 K | |||
| Cash Per Share | 0.06 X | |||
| Total Debt | 466.84 K | |||
| Debt To Equity | 0.31 % | |||
| Book Value Per Share | 4.95 X | |||
| Cash Flow From Operations | (465.77 K) | |||
| Earnings Per Share | 1.08 X | |||
About Pd-Rx Pharmaceutical Performance
Evaluating Pd-Rx Pharmaceutical's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Pd-Rx Pharmaceutical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pd-Rx Pharmaceutical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry in the United States. PD-Rx Pharmaceuticals, Inc. was incorporated in 1986 and is headquartered in Oklahoma City, Oklahoma. Pd-Rx Pharmaceutical operates under Medical Distribution classification in the United States and is traded on OTC Exchange.Things to note about Pd Rx Pharmaceutical performance evaluation
Checking the ongoing alerts about Pd-Rx Pharmaceutical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Pd Rx Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pd Rx Pharmaceutical currently holds about 104.55 K in cash with (465.77 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06. |
- Analyzing Pd-Rx Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pd-Rx Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining Pd-Rx Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pd-Rx Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pd-Rx Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pd-Rx Pharmaceutical's pink sheet. These opinions can provide insight into Pd-Rx Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Pd-Rx Pink Sheet Analysis
When running Pd-Rx Pharmaceutical's price analysis, check to measure Pd-Rx Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pd-Rx Pharmaceutical is operating at the current time. Most of Pd-Rx Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Pd-Rx Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pd-Rx Pharmaceutical's price. Additionally, you may evaluate how the addition of Pd-Rx Pharmaceutical to your portfolios can decrease your overall portfolio volatility.